Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (1021-1030 of 1,834) with videos related to

Pageof 184
Sort By:
Mabs|December 15, 2024
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflowsCaitlin Fawcett, Joseph R Tickle, Charlotte H Coles
Mabs|October 13, 2024
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administrationPaul Tamburini, Dennis Vestergaard Pedersen, Denise Devore, et al.
Mabs|October 22, 2024
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycanKaori Mukai, Robert Cost, Xin Sheen Zhang, et al.
Mabs|September 16, 2024
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved productsPhilip Green, Andreas Schneider, Jakob Lange
Mabs|November 2, 2024
Understanding the impacts of dual methionine oxidations in complementarity-determining regions on the structure of monoclonal antibodiesBo Zhao, Joy Yoon, Bojie Zhang, et al.
Mabs|February 27, 2025
YAbS: The Antibody Society's antibody therapeutics databasePuneet Rawat, Silvia Crescioli, R Prabakaran, et al.
Mabs|February 17, 2025
Quantifying antibody binding: techniques and therapeutic implicationsJames Lodge, Lewis Kajtar, Rachel Duxbury, et al.
Mabs|February 19, 2025
Targeting γc family cytokines with biologics: current status and future prospectsFabian Bick, Christophe Blanchetot, Bart N Lambrecht, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Mabs|August 28, 2024
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developabilityFortunato Ferrara, Adeline Fanni, Andre A R Teixeira, et al.
Pageof 184

Showing results (1021-1030 of 1,834) with videos related to

Sort By:
Pageof 184
Mabs|December 15, 2024
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflowsCaitlin Fawcett, Joseph R Tickle, Charlotte H Coles
Mabs|October 13, 2024
Characterization of the bispecific VHH antibody tarperprumig (ALXN1820) specific for properdin and designed for low-volume administrationPaul Tamburini, Dennis Vestergaard Pedersen, Denise Devore, et al.
Mabs|October 22, 2024
Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycanKaori Mukai, Robert Cost, Xin Sheen Zhang, et al.
Mabs|September 16, 2024
Navigating large-volume subcutaneous injections of biopharmaceuticals: a systematic review of clinical pipelines and approved productsPhilip Green, Andreas Schneider, Jakob Lange
Mabs|November 2, 2024
Understanding the impacts of dual methionine oxidations in complementarity-determining regions on the structure of monoclonal antibodiesBo Zhao, Joy Yoon, Bojie Zhang, et al.
Mabs|February 27, 2025
YAbS: The Antibody Society's antibody therapeutics databasePuneet Rawat, Silvia Crescioli, R Prabakaran, et al.
Mabs|February 17, 2025
Quantifying antibody binding: techniques and therapeutic implicationsJames Lodge, Lewis Kajtar, Rachel Duxbury, et al.
Mabs|February 19, 2025
Targeting γc family cytokines with biologics: current status and future prospectsFabian Bick, Christophe Blanchetot, Bart N Lambrecht, et al.
Mabs|August 29, 2024
IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine releaseJohn S Schardt, Even Walseng, Kim Le, et al.
Mabs|August 28, 2024
A next-generation Fab library platform directly yielding drug-like antibodies with high affinity, diversity, and developabilityFortunato Ferrara, Adeline Fanni, Andre A R Teixeira, et al.
Pageof 184